{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:05:53Z","timestamp":1793203553739,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ecl.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:34:33Z","timestamp":1779190473000},"page":"525-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes"],"prefix":"10.1016","volume":"55","author":[{"given":"Zeb I.","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ecl.2026.04.006_bib1","doi-asserted-by":"crossref","first-page":"e2032","DOI":"10.1210\/clinem\/dgaa015","article-title":"Risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry","volume":"105","author":"Shah","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.006_bib2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","article-title":"Temporal patterns in overweight and obesity in type 1 diabetes","volume":"27","author":"Conway","year":"2010","journal-title":"Diabet Med"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.006_bib3","doi-asserted-by":"crossref","first-page":"e2526353","DOI":"10.1001\/jamanetworkopen.2025.26353","article-title":"Trends and disparities in technology use and glycemic control in type 1 diabetes","volume":"8","author":"Fang","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2014.16425","article-title":"Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010","volume":"313","author":"Livingstone","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.04.006_bib5","series-title":"Diabetes in America. National Institute of Diabetes and digestive and kidney diseases (US)","article-title":"Mortality in type 1 diabetes","author":"Secrest","year":"2018"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11883-025-01369-w","article-title":"Semaglutide and tirzepatide for the treatment of obesity and weight-related comorbidities: a narrative review","volume":"28","author":"Saeed","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.006_bib7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.04.006_bib8","first-page":"S183","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in Diabetes\u20142026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"109","author":"Park","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2026.04.006_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.eprac.2025.06.027","article-title":"Noninsulin therapies in management of type 1 diabetes","volume":"31","author":"Saeed","year":"2025","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.006_bib11","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.006_bib12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.006_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41366-023-01429-8","article-title":"The emergence of obesity in type 1 diabetes","volume":"48","author":"Kueh","year":"2024","journal-title":"Int J Obes"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.006_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70126","article-title":"Insulin resistance in type 1 diabetes: concepts and implications for therapy","volume":"17","author":"Bloomgarden","year":"2025","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.006_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in U.S. adults with type 1 diabetes","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-024-02145-x","article-title":"Double diabetes\u2014when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition","volume":"23","author":"Bielka","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.ecl.2026.04.006_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrendo.2012.47","article-title":"Cardiovascular risk in double diabetes mellitus--when two worlds collide","volume":"8","author":"Cleland","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.04.006_bib18","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/dom.13848","article-title":"Double diabetes: a distinct high-risk group?","volume":"21","author":"Kietsiriroje","year":"2019","journal-title":"Diabetes Obes Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41387-019-0101-1","article-title":"Double or hybrid diabetes: a systematic review on disease prevalence, characteristics and risk factors","volume":"9","author":"Khawandanah","year":"2019","journal-title":"Nutr Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.04.006_bib20","first-page":"S27","article-title":"Diagnosis and classification of diabetes: standards of care in Diabetes\u20142026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.006_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/dia.2024.0481","article-title":"Cardiovascular and renal biomarkers in overweight and Obese adults with type 1 diabetes treated with tirzepatide for 21 months","volume":"27","author":"Garg","year":"2025","journal-title":"Diabetes Technol Therapeut"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med J"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.006_bib24","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/dom.16290","article-title":"Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market clarity database","volume":"27","author":"Hankosky","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.ecl.2026.04.006_bib25","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1111\/dom.16330","article-title":"Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: results from the veradigm\u00ae database","volume":"27","author":"Hunter","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.006_bib26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/dc24-1082","article-title":"Real-World use of semaglutide for weight management: patient characteristics and dose Titration-A Danish cohort study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.04.006_bib27","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-Week flexible titration regimen versus label-recommended 8-Week semaglutide titration regimen","volume":"48","author":"Eldor","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/cd24-0067","article-title":"Insulin titration recommendations when using glucagon-like peptide 1 receptor agonist therapy in adults with type 1 diabetes","volume":"43","author":"Saeed","year":"2024","journal-title":"Clin Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.04.006_bib29","first-page":"S146","article-title":"Diabetes technology: standards of care in Diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ecl.2026.04.006_bib30","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s13300-024-01592-9","article-title":"Changes in basal and bolus insulin requirements with tirzepatide as an adjunctive therapy in adults with type 1 diabetes using tandem Control-IQ","volume":"15","author":"Karakus","year":"2024","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.006_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2025.100298","article-title":"GLP-1 receptor agonist therapy and pregnancy: evolving and emerging evidence","volume":"25","author":"Varughese","year":"2025","journal-title":"Clin Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.04.006_bib32","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jamainternmed.2024.2919","article-title":"Tirzepatide-Induced rapid weight loss-related thyrotoxicosis","volume":"184","author":"Karakus","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.006_bib33","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clinthera.2023.02.003","article-title":"Use and interchange of incretin mimetics in the treatment of metabolic diseases: a narrative review","volume":"45","author":"Teague","year":"2023","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ecl.2026.04.006_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eprac.2024.09.117","article-title":"Characterization of interchanging incretin analogs in clinical practice: a descriptive report","volume":"31","author":"Hvisdas","year":"2025","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.ecl.2026.04.006_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2337\/cd23-0023","article-title":"Special report: potential strategies for addressing GLP-1 and dual GLP-1\/GIP receptor agonist shortages","volume":"41","author":"Whitley","year":"2023","journal-title":"Clin Diabetes. Summer"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.006_bib36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like Peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.ecl.2026.04.006_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"issue":"2","key":"10.1016\/j.ecl.2026.04.006_bib38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int J Eat Disord"},{"issue":"4","key":"10.1016\/j.ecl.2026.04.006_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.70085","article-title":"A qualitative analysis of patient experiences using semaglutide 2.4 mg for weight loss","volume":"11","author":"Plenn","year":"2025","journal-title":"Obes Sci Pract"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:24:27Z","timestamp":1785367467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0889852926000277"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}